Literature DB >> 35218508

Therapy-induced bone changes in oncology imaging with 18F-sodium fluoride (NaF) PET-CT.

Najeeb Ahmed1,2, Alyaa Sadeq3, Fahad Marafi3, Gopinath Gnanasegaran4, Sharjeel Usmani5,6.   

Abstract

18F-Sodium fluoride (18F-NaF) is a PET tracer that is mostly used in the evaluation of bone metastasis in oncology cases. Recently, 18F-NaF PET/CT is gaining wide popularity owing to its higher sensitivity over the other conventional bone tracer with higher and rapid single-pass extraction, negligible plasma protein binding, rapid blood, and renal clearance. In the era of constant evolution of cancer therapy regimens, considerable bone health impact is seen in the form of avascular necrosis, insufficiency fractures, among others. A significant number of these therapy-induced changes show high bone turnover and thereby 18F-NaF accumulation, mimicking metastatic lesions. This article summarizes and illustrates the pattern and morphological features of 18F-NaF PET/CT findings in these changes in the context of clinical and therapeutic history.
© 2022. The Author(s) under exclusive licence to The Japanese Society of Nuclear Medicine.

Entities:  

Keywords:  18F-NaF PET–CT; Bone metastases; Cancer; Therapy-induced changes

Mesh:

Substances:

Year:  2022        PMID: 35218508     DOI: 10.1007/s12149-022-01730-y

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  42 in total

1.  SNM practice guideline for sodium 18F-fluoride PET/CT bone scans 1.0.

Authors:  George Segall; Dominique Delbeke; Michael G Stabin; Einat Even-Sapir; Joanna Fair; Rebecca Sajdak; Gary T Smith
Journal:  J Nucl Med       Date:  2010-11       Impact factor: 10.057

Review 2.  Molecular mechanisms of bone 18F-NaF deposition.

Authors:  Johannes Czernin; Nagichettiar Satyamurthy; Christiaan Schiepers
Journal:  J Nucl Med       Date:  2010-11-15       Impact factor: 10.057

3.  [18F]-fluoride positron emission tomography for imaging condylar hyperplasia.

Authors:  S Laverick; G Bounds; Wai Lup Wong
Journal:  Br J Oral Maxillofac Surg       Date:  2008-10-15       Impact factor: 1.651

4.  (18)F-NaF PET/CT: EANM procedure guidelines for bone imaging.

Authors:  M Beheshti; F M Mottaghy; F Paycha; F F F Behrendt; T Van den Wyngaert; I Fogelman; K Strobel; M Celli; S Fanti; F Giammarile; B Krause; W Langsteger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-07-23       Impact factor: 9.236

Review 5.  Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate.

Authors:  G M Blake; S J Park-Holohan; G J Cook; I Fogelman
Journal:  Semin Nucl Med       Date:  2001-01       Impact factor: 4.446

6.  Quantitative analysis of 18F-NaF dynamic PET/CT cannot differentiate malignant from benign lesions in multiple myeloma.

Authors:  Christos Sachpekidis; Jens Hillengass; Hartmut Goldschmidt; Hoda Anwar; Uwe Haberkorn; Antonia Dimitrakopoulou-Strauss
Journal:  Am J Nucl Med Mol Imaging       Date:  2017-09-01

Review 7.  18F-NaF PET/CT of Obese Patients on a Lutetium-Yttrium Oxyorthosilicate PET/CT System: Patient Dosimetry, Optimization of Injected Activity, and Acquisition Time.

Authors:  Sharjeel Usmani; Najeeb Ahmed; Gopinath Gnanasegaran; Ahmed Musbah; Fareeda Al Kandari; Tim Van den Wyngaert
Journal:  J Nucl Med Technol       Date:  2020-12-30

8.  Differences in regional bone perfusion and turnover between lumbar spine and distal humerus: (18)F-fluoride PET study of treatment-naïve and treated postmenopausal women.

Authors:  Michelle L Frost; Glen M Blake; Gary J R Cook; Paul K Marsden; Ignac Fogelman
Journal:  Bone       Date:  2009-08-03       Impact factor: 4.398

9.  Cancer immunotherapy: imaging assessment of novel treatment response patterns and immune-related adverse events.

Authors:  Jennifer J Kwak; Sree Harsha Tirumani; Annick D Van den Abbeele; Phillip J Koo; Heather A Jacene
Journal:  Radiographics       Date:  2015 Mar-Apr       Impact factor: 5.333

Review 10.  Cancer treatment-induced bone loss (CTIBL): pathogenesis and clinical implications.

Authors:  S D'Oronzo; S Stucci; M Tucci; F Silvestris
Journal:  Cancer Treat Rev       Date:  2015-09-15       Impact factor: 12.111

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.